
|Videos|August 22, 2022
Dr. Packiam on background of study of sequential intravesical chemo in BCG-naïve NMIBC
Author(s)Urology Times staff
Advertisement
Vignesh Packiam, MD, explains the background of the study, “Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer,” which was published in the Journal of Urology. Packiam is a clinical assistant professor of Urology, Department of Urology, University of Iowa Hospitals and Clinics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Higher intake of ultra-processed food associated with increased prostate cancer risk
2
Jessica Yih, MD, highlights data on testosterone therapy in women
3
Real-world data support PSA below 0.2 ng/mL as key response threshold in mCSPC
4
Narmina Khanmammadova, MD, discusses findings on pelvic floor therapy before HoLEP
5









